市場調查報告書
商品編碼
1316287
全球左心室輔助裝置 (LVAD) 市場 - 2023-2030 年Global Left Ventricular Assist Device (LVAD) Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2022 年,全球左心室輔助裝置(LVAD) 市場規模達到14 億美元,預計到2030 年將實現利潤豐厚的成長,達到23 億美元。在預測期內(2023-2030 年),全球左心室輔助裝置(LVAD) 市場的複合年成長率預計將達到7.2%。
左心室輔助裝置(VAD)是一種機械循環支持策略,通過將血液從心臟腔室泵送至全身,在心衰患者中廣泛應用。預計在預測期內,心力衰竭人數的增加、新產品的推出、技術的進步和市場的不斷發展等因素將推動全球左心室輔助裝置(LVAD)市場的成長。
預計在預測期內,心力衰竭病例的增加將推動全球左心室輔助裝置市場的成長。心力衰竭極為典型。儘管在治療多種心臟疾病方面取得了進展,但心力衰竭仍是全球日益關注的問題。例如,根據美國心力衰竭協會(Heart Failure Society of America)的評估,目前有近650 萬20 歲以上的美國人患有心力衰竭。一項重要的調查評估顯示,每年有超過96 萬名新的心力衰竭患者。心力衰竭不僅是一個影響相當多的人的重大問題,而且心力衰竭甚至是一個突出的殺手。在美國,心力衰竭直接導致的死亡人數約佔所有心臟病死亡人數的8.5%。據估計,心力衰竭導致的死亡人數約佔心血管疾病死亡總人數的36%。
越來越多的研究活動預計將推動全球左心室輔助裝置市場的發展。例如,在確保獲得FDA 授權的首要行動中,總部位於以色列的設備製造商Magenta Medical 正在對其用於高風險經皮冠狀動脈介入治療(HR-PCI)的Elevate 經皮左心室輔助裝置(pLVAD)啟動一項不成熟的可行性調查。
據估計,在預測期內,植入左心室輔助裝置的高昂費用將阻礙全球左心室輔助裝置市場的發展。例如,根據美國國立衛生研究院(NIH)的數據,植入LVAD 的平均費用為175,420 美元。然而,LVAD 證明心力衰竭患者的生活品質得到了改善,但由於頻繁的再入院和昂貴的後續護理,終生成本大幅增加。
COVID-19 在全球許多國家的流行和封鎖影響了各行各業公司的財務健康。因此,在COVID-19 公共衛生緊急事件期間,美國食品和藥物管理局(FDA) 發布了指導方針,其中包括幫助申辦者和研究人員的一般注意事項,以確保試驗參與者的安全、遵守良好臨床實踐(GCP),並最大限度地降低試驗完整性的風險。
俄羅斯與烏克蘭的衝突被認為對全球左心室輔助裝置(LVAD)市場的影響不大,因為該地區的心力衰竭發病率較低,而且缺乏主要的市場參與者。儘管烏克蘭軍隊繼續抵禦俄羅斯軍隊的入侵,但由於死亡人數不斷增加,醫療援助有限,烏克蘭的診所也不得不這樣做。所有類型的藥品都出現短缺。同樣,原料進出口的重要性預計將在預測期內對全球左心室輔助裝置(LVAD)市場的成長產生輕微影響。
The global left ventricular assist device (LVAD) market reached US$ 1.4 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 2.3 billion by 2030. The global left ventricular assist device (LVAD) market is expected to exhibit a CAGR of 7.2% during the forecast period (2023-2030).
Left Ventricular Assist Devices (VAD) are mechanical circulatory support strategies planted in heart failure individuals with intense manifestation and operation by pumping blood from the chambers of the heart to the entire body. The increase in the number of heart failures, rising type launches, advancements, and increasing market developments are among the factors expected to boost the global left ventricular assist device (LVAD) market growth in the forecast period.
The increasing cases of heart failure are expected to boost the global left ventricle assist device market growth in the forecast period. Heart failure is extremely typical. Although improvement is created in the treatment of multiple states of heart conditions, heart failure is a growing concern globally. For instnace, according to the Heart Failure Society of America, the current assessments are that nearly 6.5 million Americans over the age of 20 suffer heart failure. One significant investigation assessment indicates that there are over 960,000 fresh heart failure patients yearly. Not only is heart failure a significant issue impacting a considerable number of individuals, but heart failure is even a prominent killer. Heart failure directly accounts for approximately 8.5% of all heart condition deaths in the United States. And, to some assessments, heart failure contributes to about 36% of all cardiovascular disease deaths.
Increasing research initiatives are estimated to boost the global For instance, in the foremost action in ensuring FDA authorization, Israel-based device maker Magenta Medical is initiating a premature feasibility investigation with its Elevate percutaneous Left Ventricular Assist Device (pLVAD) for high-risk percutaneous coronary intervention (HR-PCI).
The high cost of LVAD implantation is estimated to hamper the global left ventricular assist device market growth in the forecast period. For instance, according to the NIH, the mean cost of LVAD implantation was USD 175,420. However, LVADs proven heart failure patients improved quality of life but substantially increased lifetime costs because of frequent readmissions and costly follow-up care.
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
The Russia-Ukraine conflict is thought to hold a moderate influence on the global left ventricular assist device (LVAD) market, as there is a low incidence of heart failure and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of raw materials are expected to slightly impact the global Left Ventricular Assist Device (LVAD) market growth in the forecast period.
The global left ventricular assist device (LVAD) market is segmented based on type, pump type, application, end-user, and region.
Owing to the increase in the procedures of implantable LVAD, implantable LVAD is estimated to hold around 23.9% of the global market share by 2030. For instnace, in July 2022, a team from Emory's Heart and Vascular Center conducted its 500th continuous flow, durable left ventricular assist device (LVAD) implantation, additionally establishing Emory Healthcare's position as a national leader in the life-saving procedure.
Owing to the key player's efforts in the Europe region, the region is estimated to hold around 27.1% of the global market share. For instance, UK-based Calon Cardio-Technology Ltd. seeks to obtain the CE Mark for its MiniVAD in earlier 2024, by which period a US FDA Early Feasibility Study is expected to have been concluded. The corporation pursues to boost investments of almost USD 47 million (£34 million) to USD 60 million (£43 million) to finance its clinical investigations of the MiniVAD in the US and Europe from 2020 to 2023.
The major global players in the Left Ventricular Assist Device (LVAD) market include: CorWave, Apaxis Inc., Sunshine Heart, HeartWare International (Medtronic), Sun Medical Technology Research, Abiomed, Terumo Corporation, Evaheart, Jarvik Heart, and Thoratec (Abbott), among others.
The global left ventricular assist device (LVAD) market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Australia
LIST NOT EXHAUSTIVE